middle.news
Dimerix Wraps Phase 3 Recruitment, Eyes FDA Nod with $38.5M Cash in Hand
9:50am on Thursday 29th of January, 2026 AEDT
•
Healthcare
Read Story
Dimerix Wraps Phase 3 Recruitment, Eyes FDA Nod with $38.5M Cash in Hand
9:50am on Thursday 29th of January, 2026 AEDT
Key Points
ACTION3 Phase 3 trial recruitment of 286 adult patients completed
FDA endorses proteinuria endpoints for marketing approval pathway
Successful PARASOL collaboration data analysis supports trial design
Cash position of AU$38.5 million with AU$11.1 million net operating outflows
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
DIMERIX (ASX:DXB)
OPEN ARTICLE